Treats acute lymphoblastic leukemia (ALL). ANDA 201749, held by Sun Pharmaceutical Industries. Methotrexate Sodium.
As of Nov 19, 2026, ANDA 201749 (Methotrexate Sodium), held by Sun Pharmaceutical Industries, was first approved by FDA on May 21, 2015, with 4 approved supplements and 0 published complete response letters.
Methotrexate tablets are dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen Treatment of adults with mycosis fungoides Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen Treatment of adults with rheumatoid arthritis Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) Treatment of adults with severe psoriasis 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 21, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 8, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 21, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters